{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:00:45Z","timestamp":1780347645279,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,7]]},"DOI":"10.7759\/cureus.83686","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T01:26:31Z","timestamp":1746667591000},"source":"Crossref","is-referenced-by-count":1,"title":["Dual Autoimmunity: A Case Report of the Sequential Development of Systemic Lupus Erythematosus in a Patient With Anti-MDA5 Dermatomyositis"],"prefix":"10.7759","author":[{"given":"Lorena A","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis  M","family":"Vil\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15358","article-title":"Idiopathic inflammatory myopathies: a review","volume":"51","author":"Ashton C","year":"2021","unstructured":"Ashton C, Paramalingam S, Stevenson B, Brusch A, Needham M. Idiopathic inflammatory myopathies: a review. Intern Med J. 2021, 51:845-52. 10.1111\/imj.15358","journal-title":"Intern Med J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24786","article-title":"Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study","volume":"75","author":"Kronzer VL","year":"2023","unstructured":"Kronzer VL, Kimbrough BA, Crowson CS, Davis JM 3rd, Holmqvist M, Ernste FC. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res (Hoboken). 2023, 75:348-55. 10.1002\/acr.24786","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5215","article-title":"Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?","volume":"9","author":"Khanna U","year":"2021","unstructured":"Khanna U, Galimberti F, Li Y, Fernandez AP. Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?. Ann Transl Med. 2021, 9:432. 10.21037\/atm-20-5215","journal-title":"Ann Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg IE","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al.. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017, 76:1955-64. 10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer M","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, et al.. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019, 71:1400-12. 10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/life12081108","article-title":"Anti-MDA5 amyopathic dermatomyositis-a diagnostic and therapeutic challenge","volume":"12","author":"Bobirca A","year":"2022","unstructured":"Bobirca A, Alexandru C, Musetescu AE, et al.. Anti-MDA5 amyopathic dermatomyositis-a diagnostic and therapeutic challenge. Life (Basel). 2022, 12:1108. 10.3390\/life12081108","journal-title":"Life (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000908","article-title":"Anti-MDA5 dermatomyositis: an update from bench to bedside","volume":"34","author":"Fuzzi E","year":"2022","unstructured":"Fuzzi E, Gatto M, Zen M, Franco C, Zanatta E, Ghirardello A, Doria A. Anti-MDA5 dermatomyositis: an update from bench to bedside. Curr Opin Rheumatol. 2022, 34:365-73. 10.1097\/BOR.0000000000000908","journal-title":"Curr Opin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151695","article-title":"Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients","volume":"14","author":"Qian J","year":"2023","unstructured":"Qian J, Li R, Chen Z, Cao Z, Lu L, Fu Q. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front Immunol. 2023, 14:1151695. 10.3389\/fimmu.2023.1151695","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320918021","article-title":"Inflammatory myositis in systemic lupus erythematosus","volume":"29","author":"Bitencourt N","year":"2020","unstructured":"Bitencourt N, Solow EB, Wright T, Bermas BL. Inflammatory myositis in systemic lupus erythematosus. Lupus. 2020, 29:776-81. 10.1177\/0961203320918021","journal-title":"Lupus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4081\/cp.2011.e89","article-title":"Systemic lupus erythematosus myositis overlap syndrome: report of 6 cases","volume":"1","author":"Maazoun F","year":"2011","unstructured":"Maazoun F, Frikha F, Snoussi M, Kaddour N, Masmoudi H, Bahloul Z. Systemic lupus erythematosus myositis overlap syndrome: report of 6 cases. Clin Pract. 2011, 1:e89. 10.4081\/cp.2011.e89","journal-title":"Clin Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1874312901610010122","article-title":"Anti-MDA5 antibody dermatomyositis overlap with systemic lupus erythematosus: a case report and review of the literature","volume":"10","author":"Milam EC","year":"2016","unstructured":"Milam EC, Futran J, Franks AG Jr. Anti-MDA5 antibody dermatomyositis overlap with systemic lupus erythematosus: a case report and review of the literature. Open Rheumatol J. 2016, 10:122-8. 10.2174\/1874312901610010122","journal-title":"Open Rheumatol J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejr.2021.02.003","article-title":"Subacute cutaneous lupus erythematosus, and positive anti-MDA5 antibody in clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease: a case report and literature review","volume":"43","author":"Sulaiman W","year":"2021","unstructured":"Sulaiman W, Heng YHA, Lee BR, Subramaniam R. Subacute cutaneous lupus erythematosus, and positive anti-MDA5 antibody in clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease: a case report and literature review. Egypt Rheumatol. 2021, 43:197-202. 10.1016\/j.ejr.2021.02.003","journal-title":"Egypt Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1439807","article-title":"Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues","volume":"15","author":"Wu Y","year":"2024","unstructured":"Wu Y, Luo J, Duan L. Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues. Front Immunol. 2024, 15:1439807. 10.3389\/fimmu.2024.1439807","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103648","article-title":"Immunopathogenesis of systemic lupus erythematosus: an update","volume":"23","author":"Arnaud L","year":"2024","unstructured":"Arnaud L, Chasset F, Martin T. Immunopathogenesis of systemic lupus erythematosus: an update. Autoimmun Rev. 2024, 23:103648. 10.1016\/j.autrev.2024.103648","journal-title":"Autoimmun Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.833114","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system","volume":"8","author":"Hu H","year":"2021","unstructured":"Hu H, Yang H, Liu Y, Yan B. Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system. Front Med (Lausanne). 2021, 8:833114. 10.3389\/fmed.2021.833114","journal-title":"Front Med (Lausanne)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1467257","article-title":"Current diagnosis and treatment of polymyositis and dermatomyositis","volume":"28","author":"Sasaki H","year":"2018","unstructured":"Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018, 28:913-21. 10.1080\/14397595.2018.1467257","journal-title":"Mod Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073980","article-title":"Advances in the management of systemic lupus erythematosus","volume":"383","author":"Morand EF","year":"2023","unstructured":"Morand EF, Fernandez-Ruiz R, Blazer A, Niewold TB. Advances in the management of systemic lupus erythematosus. BMJ. 2023, 383:e073980. 10.1136\/bmj-2022-073980","journal-title":"BMJ"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363875-dual-autoimmunity-a-case-report-of-the-sequential-development-of-systemic-lupus-erythematosus-in-a-patient-with-anti-mda5-dermatomyositis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T01:26:31Z","timestamp":1746667591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363875-dual-autoimmunity-a-case-report-of-the-sequential-development-of-systemic-lupus-erythematosus-in-a-patient-with-anti-mda5-dermatomyositis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.83686","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}